New safety check for modern bleeding treatment in indian hemophilia patients
NCT ID NCT07446010
Summary
This study will monitor the safety and real-world use of Octocog alfa, a lab-made clotting factor, in Indian adults with severe Hemophilia A. It will include 33 male patients who have previously received clotting factor treatment and are using Octocog alfa to treat bleeding episodes as needed. Researchers will track side effects, treatment patterns, and how well bleeding is controlled during routine medical care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
All India Institute Of Medical Sciences
New Delhi, India
-
Christian Medical College & Hospital
Ludhiana, India
-
Department of Medicine Assam Medical College & Hospital
Dibrugarh, India
-
Government of Medical College Kozhikode
Kozhikode, India
-
Sahyadri Super Speciality Hospital
Pune, India
-
Sanjay Gandhi Post Graduate Institute & Medical Sciences
Lucknow, India
Conditions
Explore the condition pages connected to this study.